SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is seeing renewed momentum driven by strong prescription data and positive sentiment surrounding the oral Wegovy rollout, which is being viewed as a strategic advantage against competitors. Investors are closely watching the upcoming earnings report, with community discussions heavily focused on the company's ability to maintain its market position through potential M&A and improved guidance.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently experiencing heightened retail activity and speculative momentum driven by its integration into the broader Japanese blockchain and IoT data economy narratives. While the community is actively debating the potential impact of ecosystem expansions like Janction, sentiment remains divided between long-term holders accumulating positions and skeptics focused on historical price underperformance.

Everspin Technologies, Inc. engages in the provision of magnetoresistive random access memory (MRAM) solutions. Its products include Toggle MRAM, Spin-transfer Torque MRAM, TMR Sensors, and Embedded MRAM. The company was founded by Saied Tehrani on May 16, 2008 and is headquartered in Chandler, AZ.

Everspin Technologies Inc

Everspin Technologies is seeing significant momentum and retail interest as investors connect the company's specialized MRAM technology to broader AI memory and aerospace growth narratives. Market participants are actively debating the sustainability of this rapid move, with bulls pointing to recent defense contracts and low float as catalysts for a potential squeeze, while some skeptics express concerns over high valuations and technical resistance.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternate care testing sites. The Nutritional Products segment caters to the worldwide sales of pediatric and adult nutritional products. The Medical Devices segment includes a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Abbott Laboratories

Abbott Laboratories is experiencing significant downward pressure as investors weigh disappointing earnings guidance and the financial implications of its recent acquisition of Exact Sciences. The community is actively debating whether the current price levels represent a deep-value buying opportunity or a value trap amid ongoing litigation concerns and broader institutional de-risking within the healthcare sector.

Investment Managers Series Trust II - Tradr 2X Short SNDK Daily ETF

Tradr 2X Short SNDK Daily ETF

Tradr 2X Short SNDK Daily ETF (SNDQ) is seeing significant volume and trader attention as market participants attempt to hedge against the rapid, parabolic price appreciation in SanDisk (SNDK). The community is actively debating the sustainability of the semiconductor sector's momentum, with many users employing SNDQ as a tactical vehicle to bet on a potential correction or reversal.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending following an FDA meeting to define the pivotal Phase 3 registration path for CAD-1005 in treating heparin-induced thrombocytopenia, though community sentiment remains polarized due to concerns over high-frequency social media spamming and future dilution risks.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy is trending following a successful IPO that saw significant interest due to its strategic backing by Amazon and its position as a key infrastructure player in the AI power-demand narrative. The community is actively debating the company's valuation compared to peers, with investors highlighting the company's industrial partnerships and proprietary TRISO fuel technology as major differentiators for long-term scalability.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as shareholders react to reports that FDA Commissioner Marty Makary may be replaced, a move widely interpreted by the community as a positive catalyst that could alleviate regulatory friction for the company's oncology pipeline. Investors are actively discussing the potential for smoother sBLA reviews and increased global expansion, fueling bullish sentiment despite recent volatility and ongoing legal disputes.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Investors are intensely debating the sustainability of the semiconductor sector's parabolic rally, with many retail traders actively seeking entry points into leveraged bear positions like SOXS despite consistent losses from decay and sustained momentum. The community is sharply divided between those who believe the AI-driven 'super cycle' is a long-term wealth generator and those convinced the sector is a historic bubble fueled by unsustainable hype, circular financing, and extreme market manipulation.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna shares have surged following the company's disclosure of early-stage research into an mRNA-based vaccine for the rodent-borne hantavirus. The stock is currently a focus for traders betting on speculative momentum and potential pandemic-era dynamics, with active community discussion centering on vaccine platform versatility and ongoing oncology pipeline developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

EU Banks Get Breathing Room as Capital Rule Decisions Face Delays

EU delays FRTB capital rules again, giving DB, BCS and BNPQY near-term relief while uncertainty lingers over Basel III rollout.

BNP Paribas (BNPQY) Upgraded to Buy: Here's What You Should Know

BNP Paribas (BNPQY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BNPQY vs. NABZY: Which Stock Is the Better Value Option?

Should Value Investors Buy BNP Paribas (BNPQY) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

What Makes BNP Paribas SA (BNPQY) a Strong Momentum Stock: Buy Now?

Does BNP Paribas SA (BNPQY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are Investors Undervaluing BNP Paribas (BNPQY) Right Now?

BNPQY vs. NABZY: Which Stock Should Value Investors Buy Now?

Toronto Dominion Bank (The) (TD) Hits Fresh High: Is There Still Room to Run?

Toronto-Dominion (TD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

BNP Paribas SA (BNPQY) Is Up 3.16% in One Week: What You Should Know 

Is BNP Paribas (BNPQY) Stock Undervalued Right Now?

BNP Paribas SA engages in the provision of banking and financial services. It operates through the following segments: Corporate and Institutional Banking (CIB); Commercial, Personal Banking, and Services (CPBS); Investment and Protection Services (IPS); and Other Activities. The CIB segment covers global banking, global markets, and securities services. The CPBS segment includes commercial and personal banking in France, Italy, Belgium, and Luxembourg, as well as outside the Eurozone, which is organized around Europe-Mediterranean, to cover central and eastern Europe and Turkey. The IPS segment is involved in insurance, wealth and asset management, and management of unlisted and listed industrial and commercial investments. The Other Activities segment refers to the group’s central treasury function, some costs related to cross-business projects, the residential mortgage lending business of personal finance, and certain investments. The company was founded in 1822 and is headquartered in Paris, France.

BNP Paribas - ADR - Level I

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$1.89	--	--	N/A
Q1 '26	$1.53	--	--	N/A
Q4 '25	$1.37	--	--	N/A
Q3 '25	$1.53	$1.57	2.69%	BEAT
Q2 '25	$1.52	$1.54	1.65%	BEAT

BNPQY
BNP PARIBAS/S ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings

Latest BNPQY News

BNPQYBNP PARIBAS/S ADR